Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

1.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

2.

A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis.

Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z, Ringner-Nackter L, Higgs CJ, Herold BC, Gazzard BG, Boffito M.

Clin Pharmacol Ther. 2014 Sep;96(3):314-23. doi: 10.1038/clpt.2014.118. Epub 2014 May 26.

PMID:
24862215
3.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

4.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

5.

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.

Vrouenraets SM, Wit FW, Fernandez Garcia E, Moyle GJ, Jackson AG, Allavena C, Raffi F, Jayaweera DT, Mauss S, Katlama C, Fisher M, Slama L, Hardy WD, Dejesus E, van Eeden A, Reiss P; BASIC Study Group.

HIV Med. 2011 Nov;12(10):620-31. doi: 10.1111/j.1468-1293.2011.00941.x. Epub 2011 Aug 7.

PMID:
21819530
6.

Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.

Randell PA, Jackson AG, Boffito M, Back DJ, Tjia JF, Taylor J, Mandalia S, Moyle GJ.

Antivir Ther. 2010;15(8):1125-32. doi: 10.3851/IMP1675.

PMID:
21149919
7.

The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.

Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ.

Antivir Ther. 2010;15(2):227-33. doi: 10.3851/IMP1518.

PMID:
20386078
8.

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447.

9.

Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.

Ware LJ, Jackson AG, Wootton SA, Burdge GC, Morlese JF, Moyle GJ, Jackson AA, Gazzard BG.

Br J Nutr. 2009 Oct;102(7):1038-46. doi: 10.1017/S0007114509338817. Epub 2009 Jun 1.

PMID:
19480729
10.

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.

AIDS. 2009 Jan 2;23(1):71-82. doi: 10.1097/QAD.0b013e32831cc129.

11.

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group.

AIDS. 2008 Nov 12;22(17):2279-89. doi: 10.1097/QAD.0b013e328311d16f.

12.

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD.

Ann Intern Med. 2008 Sep 2;149(5):289-99.

PMID:
18765698
13.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN.

J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523.

14.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.

15.
16.

Racial differences in clinically localized prostate cancers of black and white men.

deVere White RW, Deitch AD, Jackson AG, Gandour-Edwards R, Marshalleck J, Soares SE, Toscano SN, Lunetta JM, Stewart SL.

J Urol. 1998 Jun;159(6):1979-82; discussion 1982-3.

PMID:
9598502
17.

Preparation of TEM foils from Nb-10 a/o Si.

Cockeram B, Jackson AG, Omlor RE, Srinivasan R, Weiss I.

Microsc Res Tech. 1992 Aug 1;22(3):298-300.

PMID:
1504356
18.

Penile prosthesis in the management of priapism.

Mireku-Boateng A, Jackson AG.

Urol Int. 1989;44(4):247-8.

PMID:
2800061
19.

The role of diet in prostate cancer.

Kaul L, Heshmat MY, Kovi J, Jackson MA, Jackson AG, Jones GW, Edson M, Enterline JP, Worrell RG, Perry SL.

Nutr Cancer. 1987;9(2-3):123-8.

PMID:
3562290
20.

The ultrastructural localization of tri-n-butyltin in human erythrocyte membranes during shape transformation leading to hemolysis.

Porvaznik M, Gray BH, Mattie D, Jackson AG, Omlor RE.

Lab Invest. 1986 Mar;54(3):254-67.

PMID:
2419664
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk